Maxcyte
MaxCyte, Inc specializes in cell modification technologies that enable the discovery, development, and manufacture of various classes.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 5.7x EV/Revenue -14.9x EV/EBITDA | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 21 % | 30 % | 31 % | (7 %) | (6 %) | (4 %) | 15 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (38 %) | (49 %) | (47 %) | (107 %) | (120 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (45 %) | (56 %) | (53 %) | (92 %) | (106 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 68 % | 45 % | 44 % | 58 % | 58 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
MaxCyte operates in the biotechnology sector, specializing in scalable transfection systems that enhance cell engineering processes. The company serves a diverse range of clients including pharmaceutical companies, biotechnology firms, and academic institutions. MaxCyte's primary market is the life sciences industry, focusing on areas such as cell therapy, gene editing, and protein production. The business model revolves around selling its proprietary transfection systems and related services, which are designed to improve the efficiency, potency, and efficacy of cell-based therapies. Revenue is generated through the sale of these systems, as well as through long-term service agreements and licensing deals. MaxCyte's technology is particularly valuable for its ability to seamlessly scale from early research stages to commercial manufacturing, making it a critical tool for advancing therapeutic development.
Keywords: biotechnology, transfection systems, cell engineering, gene editing, cell therapy, protein production, life sciences, scalable technology, pharmaceutical, academic institutions.
Tech stack
Investments by Maxcyte
Edit